Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients

被引：0
|
作者：
Loupakis, F. [1 ,2 ,3 ,4 ,5 ]
Cremolini, C. [1 ,2 ,3 ,4 ,5 ]
Perrone, G. [1 ,2 ,3 ,4 ,5 ]
Stasi, I. [1 ,2 ,3 ,4 ,5 ]
Salvatore, L. [1 ,2 ,3 ,4 ,5 ]
Vincenzi, B. [1 ,2 ,3 ,4 ,5 ]
Ruzzo, A. [1 ,2 ,3 ,4 ,5 ]
Ronzoni, M. [1 ,2 ,3 ,4 ,5 ]
Bencardino, K. [1 ,2 ,3 ,4 ,5 ]
Falcone, A. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Azienda USL 6, Dept Oncol, Livorno, Italy
[2] Campus Biomed Univ, Rome, Italy
[3] Univ Urbino, Dept Biomol Sci, I-61029 Urbino, Italy
[4] Ist Sci San Raffaele, I-20132 Milan, Italy
[5] Univ Pisa, Dept Oncol, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4021
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature
    Barni, Sandro
    Ghilardi, Mara
    Borgonovo, Karen
    Cabiddu, Mary
    Zaniboni, Alberto
    Petrelli, Fausto
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (02) : 101 - 109
  • [42] Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts)
    Cremolini, Chiara
    Loupakis, Fotios
    Antoniotti, Carlotta
    Fioravanti, Anna
    Orlandi, Paola
    Salvatore, Lisa
    Canu, Bastianina
    Schirripa, Marta
    Masi, Gianluca
    Di Desidero, Teresa
    Marmorino, Federica
    Bergamo, Francesca
    Zoratto, Federica
    Bocci, Guido
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Myoung Joo Kang
    Yong Sang Hong
    Kyu-pyo Kim
    Sun Young Kim
    Ji Yeon Baek
    Min-Hee Ryu
    Jae-Lyun Lee
    Heung Moon Chang
    Mi-Jung Kim
    Hee Jin Chang
    Yoon-Koo Kang
    Tae Won Kim
    Investigational New Drugs, 2012, 30 : 1607 - 1613
  • [44] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Kang, Myoung Joo
    Hong, Yong Sang
    Kim, Kyu-pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Ryu, Min-Hee
    Lee, Jae-Lyun
    Chang, Heung Moon
    Kim, Mi-Jung
    Chang, Hee Jin
    Kang, Yoon-Koo
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1607 - 1613
  • [45] Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
    Seung Tae Kim
    Tae Jin Ahn
    Eunjin Lee
    In-Gu Do
    Su Jin Lee
    Se Hoon Park
    Joon Oh Park
    Young Suk Park
    Ho Yeong Lim
    Won Ki Kang
    Suk Hyeong Kim
    Jeeyun Lee
    Hee Cheol Kim
    BMC Cancer, 15
  • [46] Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
    Kim, Seung Tae
    Ahn, Tae Jin
    Lee, Eunjin
    Do, In-Gu
    Lee, Su Jin
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Kim, Suk Hyeong
    Lee, Jeeyun
    Kim, Hee Cheol
    BMC CANCER, 2015, 15
  • [47] A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan
    Fora, Ahmad A.
    McMahon, Jeanne A.
    Wilding, Greg
    Groman, Adrienne
    Ma, Wen Wee
    Romano, Karen S.
    Fakih, Marwan G.
    ONCOLOGY, 2013, 84 (04) : 210 - 213
  • [48] Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.
    Hayashi, Kaori
    Mitani, Seiichiro
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Sugiyama, Keiji
    Tsushima, Takahiro
    Honda, Kazunori
    Todaka, Akiko
    Masuishi, Toshiki
    Yokota, Tomoya
    Narita, Yukiya
    Machida, Nozomu
    Kadowaki, Shigenori
    Fukutomi, Akira
    Ura, Takashi
    Onozawa, Yusuke
    Ando, Masashi
    Yasui, Hirofumi
    Muro, Kei
    Yamazaki, Kentaro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [49] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
    Lawrence, D.
    Maschio, M.
    Yunger, S.
    Easaw, J.
    Aucoin, N.
    Weinstein, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
  • [50] FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
    Caglayan Geredeli
    Nurgul Yasar
    World Journal of Surgical Oncology, 16
12345